We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 15, 2020

Pembrolizumab vs Chemotherapy in Advanced Esophageal Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
J. Clin. Oncol 2020 Oct 07;[EPub Ahead of Print], T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, T Moriwaki, SB Kim, SH Lee, J Bennouna, K Kato, L Shen, P Enzinger, SK Qin, P Ferreira, J Chen, G Girotto, C de la Fouchardiere, H Senellart, R Al-Rajabi, F Lordick, R Wang, S Suryawanshi, P Bhagia, SP Kang, JP Metges

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading